Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97


Kallikrein/K1, Kinins, and ACE/Kininase II in Homeostasis and in Disease Insight From Human and Experimental Genetic Studies, Therapeutic Implication.

Alhenc-Gelas F, Bouby N, Girolami JP.

Front Med (Lausanne). 2019 Jun 27;6:136. doi: 10.3389/fmed.2019.00136. eCollection 2019. Review.


Glucagon revisited: Coordinated actions on the liver and kidney.

Bankir L, Bouby N, Speth RC, Velho G, Crambert G.

Diabetes Res Clin Pract. 2018 Dec;146:119-129. doi: 10.1016/j.diabres.2018.10.004. Epub 2018 Oct 16. Review.


Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.

El Boustany R, Tasevska I, Meijer E, Kieneker LM, Enhörning S, Lefèvre G, Mohammedi K, Marre M, Fumeron F, Balkau B, Bouby N, Bankir L, Bakker SJ, Roussel R, Melander O, Gansevoort RT, Velho G.

JCI Insight. 2018 Jul 12;3(13). pii: 121479. doi: 10.1172/jci.insight.121479.


Renal potassium handling in carriers of the Gly40Ser mutation of the glucagon receptor suggests a role for glucagon in potassium homeostasis.

Bankir L, Barbato A, Russo O, Crambert G, Iacone R, Bouby N, Perna L, Strazzullo P.

Physiol Rep. 2018 Apr;6(8):e13661. doi: 10.14814/phy2.13661.


Improved protocols for the study of urinary electrolyte excretion and blood pressure in rodents: use of gel food and stepwise changes in diet composition.

Nizar JM, Bouby N, Bankir L, Bhalla V.

Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1129-F1137. doi: 10.1152/ajprenal.00474.2017. Epub 2018 Jan 10.


Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans.

Enhörning S, Tasevska I, Roussel R, Bouby N, Persson M, Burri P, Bankir L, Melander O.

Eur J Nutr. 2019 Feb;58(1):315-324. doi: 10.1007/s00394-017-1595-8. Epub 2017 Dec 14.


Genetically increased angiotensin I-converting enzyme alters peripheral and renal vascular reactivity to angiotensin II and bradykinin in mice.

Chollet C, Placier S, Chatziantoniou C, Hus-Citharel A, Caron N, Roussel R, Alhenc-Gelas F, Bouby N.

Am J Physiol Heart Circ Physiol. 2018 Feb 1;314(2):H350-H358. doi: 10.1152/ajpheart.00356.2017. Epub 2017 Nov 3.


Neuroprotective effect of kinin B1 receptor activation in acute cerebral ischemia in diabetic mice.

Desposito D, Zadigue G, Taveau C, Adam C, Alhenc-Gelas F, Bouby N, Roussel R.

Sci Rep. 2017 Aug 25;7(1):9410. doi: 10.1038/s41598-017-09721-0.


Vasopressin and metabolic disorders: translation from experimental models to clinical use.

Nakamura K, Velho G, Bouby N.

J Intern Med. 2017 Oct;282(4):298-309. doi: 10.1111/joim.12649. Epub 2017 Sep 7. Review.


Relationship between Sodium Intake and Water Intake: The False and the True.

Bankir L, Perucca J, Norsk P, Bouby N, Damgaard M.

Ann Nutr Metab. 2017;70 Suppl 1:51-61. doi: 10.1159/000463831. Epub 2017 Jun 15. Review.


Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes.

El Boustany R, Taveau C, Chollet C, Velho G, Bankir L, Alhenc-Gelas F, Roussel R, Bouby N.

J Diabetes Complications. 2017 Jun;31(6):929-932. doi: 10.1016/j.jdiacomp.2017.04.005. Epub 2017 Apr 6.


Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1A receptors.

Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N.

Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E127-E135. doi: 10.1152/ajpendo.00269.2016. Epub 2016 Dec 20.


Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-standing Type 1 Diabetes.

Velho G, El Boustany R, Lefèvre G, Mohammedi K, Fumeron F, Potier L, Bankir L, Bouby N, Hadjadj S, Marre M, Roussel R.

Diabetes Care. 2016 Dec;39(12):2288-2295. Epub 2016 Oct 11.


Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implications.

Desposito D, Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Biol Chem. 2016 Dec 1;397(12):1217-1222. doi: 10.1515/hsz-2016-0228. Review.


Glucagon actions on the kidney revisited: possible role in potassium homeostasis.

Bankir L, Bouby N, Blondeau B, Crambert G.

Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F469-86. doi: 10.1152/ajprenal.00560.2015. Epub 2016 May 18. Review.


Hydration and Chronic Kidney Disease Progression: A Critical Review of the Evidence.

Clark WF, Sontrop JM, Huang SH, Moist L, Bouby N, Bankir L.

Am J Nephrol. 2016;43(4):281-92. doi: 10.1159/000445959. Epub 2016 May 3. Review.


Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community.

Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, Balkau B, Tichet J, Bankir L, Marre M, Velho G.

J Clin Endocrinol Metab. 2016 Jun;101(6):2432-9. doi: 10.1210/jc.2016-1113. Epub 2016 Apr 6.


[Renal medulla].

Bankir L, Bouby N.

Nephrol Ther. 2016 Apr;12 Suppl 1:S3-S20. doi: 10.1016/j.nephro.2016.02.010. Epub 2016 Mar 11. French.


Improvement of skin wound healing in diabetic mice by kinin B2 receptor blockade.

Desposito D, Chollet C, Taveau C, Descamps V, Alhenc-Gelas F, Roussel R, Bouby N, Waeckel L.

Clin Sci (Lond). 2016 Jan;130(1):45-56. doi: 10.1042/CS20150295. Epub 2015 Oct 6.


Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study.

Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G.

Am J Nephrol. 2015;42(2):107-14. doi: 10.1159/000439061. Epub 2015 Sep 9.


Urine Osmolarity and Risk of Dialysis Initiation in a CKD Cohort.

Bankir L, Plischke M, Bouby N, Haas M.

Ann Nutr Metab. 2015;66 Suppl 3:14-7. doi: 10.1159/000381240. Epub 2015 Jun 18.


Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes.

Velho G, Ragot S, Mohammedi K, Gand E, Fraty M, Fumeron F, Saulnier PJ, Bellili-Munoz N, Bouby N, Potier L, Alhenc-Gelas F, Marre M, Hadjadj S, Roussel R.

Diabetes. 2015 Sep;64(9):3262-72. doi: 10.2337/db14-1852. Epub 2015 May 6.


Protein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and urea.

Bankir L, Roussel R, Bouby N.

Am J Physiol Renal Physiol. 2015 Jul 1;309(1):F2-23. doi: 10.1152/ajprenal.00614.2014. Epub 2015 Apr 29. Review.


Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats.

Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N.

Diabetologia. 2015 May;58(5):1081-90. doi: 10.1007/s00125-015-3496-9. Epub 2015 Jan 27.


Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice.

Desposito D, Potier L, Chollet C, Gobeil F Jr, Roussel R, Alhenc-Gelas F, Bouby N, Waeckel L.

J Pharmacol Exp Ther. 2015 Feb;352(2):218-26. doi: 10.1124/jpet.114.219196. Epub 2014 Nov 14.


Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease.

Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG.

J Clin Endocrinol Metab. 2014 Dec;99(12):4656-63. doi: 10.1210/jc.2014-2295.


Apelin counteracts vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signaling pathways in the rat collecting duct.

Hus-Citharel A, Bodineau L, Frugière A, Joubert F, Bouby N, Llorens-Cortes C.

Endocrinology. 2014 Nov;155(11):4483-93. doi: 10.1210/en.2014-1257. Epub 2014 Aug 26.


Genetic manipulation and genetic variation of the kallikrein-kinin system: impact on cardiovascular and renal diseases.

Girolami JP, Blaes N, Bouby N, Alhenc-Gelas F.

Prog Drug Res. 2014;69:145-96. Review.


Protection of Wistar-Furth rats against postischaemic acute renal injury: role for nitric oxide and thromboxane?

Voisin V, Declèves AE, Hubert V, Colombaro V, Giordano L, Habsch I, Bouby N, Nonclercq D, Caron N.

Clin Exp Pharmacol Physiol. 2014 Nov;41(11):911-20. doi: 10.1111/1440-1681.12298.


Hydration and kidney health.

Bouby N, Clark WF, Roussel R, Taveau C, Wang CJ.

Obes Facts. 2014;7 Suppl 2:19-32. doi: 10.1159/000360889. Epub 2014 Apr 4. No abstract available.


Tissue kallikrein deficiency, insulin resistance, and diabetes in mouse and man.

Potier L, Waeckel L, Fumeron F, Bodin S, Fysekidis M, Chollet C, Bellili N, Bonnet F, Gusto G, Velho G, Marre M, Alhenc-Gelas F, Roussel R, Bouby N; DESIR Study Group.

J Endocrinol. 2014 Apr 22;221(2):297-308. doi: 10.1530/JOE-13-0529. Print 2014 May.


Cardioprotective effect of VEGF and venom VEGF-like protein in acute myocardial ischemia in mice: effect on mitochondrial function.

Messadi E, Aloui Z, Belaidi E, Vincent MP, Couture-Lepetit E, Waeckel L, Decorps J, Bouby N, Gasmi A, Karoui H, Ovize M, Alhenc-Gelas F, Richer C.

J Cardiovasc Pharmacol. 2014 Mar;63(3):274-81. doi: 10.1097/FJC.0000000000000045.


Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.

Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L, Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R.

Diabetes Care. 2013 Nov;36(11):3639-45. doi: 10.2337/dc13-0683. Epub 2013 Jul 17.


Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes.

Potier L, Waeckel L, Vincent MP, Chollet C, Gobeil F Jr, Marre M, Bruneval P, Richer C, Roussel R, Alhenc-Gelas F, Bouby N.

J Pharmacol Exp Ther. 2013 Jul;346(1):23-30. doi: 10.1124/jpet.113.203927. Epub 2013 Apr 16.


Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man.

Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Thromb Haemost. 2013 Sep;110(3):476-83. doi: 10.1160/TH12-12-0937. Epub 2013 Apr 4. Review.


Vasopressin: a novel target for the prevention and retardation of kidney disease?

Bankir L, Bouby N, Ritz E.

Nat Rev Nephrol. 2013 Apr;9(4):223-39. doi: 10.1038/nrneph.2013.22. Epub 2013 Feb 26. Review.


Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.

Potier L, Waeckel L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F.

Biol Chem. 2013 Mar;394(3):329-33. doi: 10.1515/hsz-2012-0332. Review.


Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse.

Waeckel L, Potier L, Chollet C, Taveau C, Bruneval P, Roussel R, Alhenc-Gelas F, Bouby N.

Endocrinology. 2012 Aug;153(8):3886-96. doi: 10.1210/en.2012-1225. Epub 2012 Jun 5.


Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort.

Enhörning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O.

Int J Obes (Lond). 2013 Apr;37(4):598-603. doi: 10.1038/ijo.2012.88. Epub 2012 May 22.


Synthesis and fragmentation of hyaluronan in renal ischaemia.

Declèves AE, Caron N, Voisin V, Legrand A, Bouby N, Kultti A, Tammi MI, Flamion B.

Nephrol Dial Transplant. 2012 Oct;27(10):3771-81. doi: 10.1093/ndt/gfs098. Epub 2012 Apr 23.


Low water intake and risk for new-onset hyperglycemia.

Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L; D.E.S.I.R. Study Group.

Diabetes Care. 2011 Dec;34(12):2551-4. doi: 10.2337/dc11-0652. Epub 2011 Oct 12.


Kinins as therapeutic agents in cardiovascular and renal diseases.

Alhenc-Gelas F, Bouby N, Richer C, Potier L, Roussel R, Marre M.

Curr Pharm Des. 2011;17(25):2654-62. Review.


Reduced insulin secretion and nocturnal dipping of blood pressure are associated with a disturbed circadian pattern of urine excretion in metabolic syndrome.

Guerrot D, Hansel B, Perucca J, Roussel R, Bouby N, Girerd X, Bankir L.

J Clin Endocrinol Metab. 2011 Jun;96(6):E929-33. doi: 10.1210/jc.2010-2337. Epub 2011 Mar 16.


Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension?

Bankir L, Bichet DG, Bouby N.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F917-28. doi: 10.1152/ajprenal.00413.2010. Epub 2010 Sep 8. Review.


Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.

Messadi E, Vincent MP, Griol-Charhbili V, Mandet C, Colucci J, Krege JH, Bruneval P, Bouby N, Smithies O, Alhenc-Gelas F, Richer C.

FASEB J. 2010 Dec;24(12):4691-700. doi: 10.1096/fj.10-165902. Epub 2010 Jul 28.


Multiple cross talk between angiotensin II, bradykinin, and insulin signaling in the cortical thick ascending limb of rat kidney.

Hus-Citharel A, Bouby N, Iturrioz X, Llorens-Cortes C.

Endocrinology. 2010 Jul;151(7):3181-94. doi: 10.1210/en.2009-1237. Epub 2010 May 12.


Kallikrein protects against microalbuminuria in experimental type I diabetes.

Bodin S, Chollet C, Goncalves-Mendes N, Gardes J, Pean F, Heudes D, Bruneval P, Marre M, Alhenc-Gelas F, Bouby N.

Kidney Int. 2009 Aug;76(4):395-403. doi: 10.1038/ki.2009.208. Epub 2009 Jun 10.


Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney.

Pizard A, Richer C, Bouby N, Picard N, Meneton P, Azizi M, Alhenc-Gelas F.

Biol Chem. 2008 Jun;389(6):701-6. doi: 10.1515/BC.2008.081. Review.


Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.

Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L.

J Am Soc Nephrol. 2008 Sep;19(9):1721-31. doi: 10.1681/ASN.2008010021. Epub 2008 Jul 2.


Effect of apelin on glomerular hemodynamic function in the rat kidney.

Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, Llorens-Cortes C.

Kidney Int. 2008 Aug;74(4):486-94. doi: 10.1038/ki.2008.199. Epub 2008 May 28.

Supplemental Content

Support Center